PLSE Pulse Biosciences Inc
Price (delayed)
$16.73
Market cap
$1.13B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.92
Enterprise value
$1.02B
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first
Highlights
PLSE's equity has soared by 159% year-on-year and by 45% since the previous quarter
The quick ratio has surged by 78% year-on-year
The company's debt rose by 6% QoQ but it fell by 2.7% YoY
The net income has declined by 27% year-on-year and by 16% since the previous quarter
PLSE's EPS is down by 15% since the previous quarter and by 8% year-on-year
Key stats
What are the main financial stats of PLSE
Market
Valuations
Earnings
Shares outstanding
67.27M
Market cap
$1.13B
Enterprise value
$1.02B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$56.26M
Net income
-$53.59M
EBIT
-$53.59M
EBITDA
-$52.41M
Free cash flow
-$36.47M
Per share
Balance sheet
Liquidity
EPS
-$0.92
EPS diluted
-$0.92
Free cash flow per share
-$0.62
Book value per share
$1.87
Revenue per share
$0
TBVPS
$2.2
Total assets
$132.46M
Total liabilities
$17.6M
Debt
$8.9M
Equity
$114.86M
Working capital
$109.39M
Debt to equity
0.08
Current ratio
11.88
Quick ratio
11.74
Net debt/EBITDA
2.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68%
Return on equity
-83.3%
Return on invested capital
-457.3%
Return on capital employed
-43.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLSE stock price
How has the Pulse Biosciences stock price performed over time
Intraday
4.96%
1 week
5.89%
1 month
-8.63%
1 year
117.56%
YTD
-3.91%
QTD
3.98%
Financial performance
How have Pulse Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.26M
Net income
-$53.59M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 29% year-on-year and by 16% since the previous quarter
The net income has declined by 27% year-on-year and by 16% since the previous quarter
Growth
What is Pulse Biosciences's growth rate over time
Valuation
What is Pulse Biosciences stock price valuation
P/E
N/A
P/B
8.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PLSE's EPS is down by 15% since the previous quarter and by 8% year-on-year
PLSE's equity has soared by 159% year-on-year and by 45% since the previous quarter
The P/B is 42% below the last 4 quarters average of 14.8 and 31% below the 5-year quarterly average of 12.3
Efficiency
How efficient is Pulse Biosciences business performance
PLSE's return on equity is up by 28% year-on-year and by 16% since the previous quarter
The ROIC has declined by 26% since the previous quarter
The ROA has grown by 11% from the previous quarter but it has contracted by 9% YoY
Dividends
What is PLSE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLSE.
Financial health
How did Pulse Biosciences financials performed over time
The company's total assets has surged by 124% YoY and by 42% QoQ
The quick ratio has surged by 78% year-on-year
The company's debt is 92% lower than its equity
PLSE's equity has soared by 159% year-on-year and by 45% since the previous quarter
The debt to equity has plunged by 62% YoY and by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.